Chemotherapy-Induced Neutropenia Treatment Market Growth, Size, Trends Analysis - By Treatment Type, By Drug Type, By Route of Administration, By Distribution Channel - Regional Outlook, Competitive Strategies and Segment Forecast to 2034
Description
Chemotherapy-Induced Neutropenia Treatment Market Introduction and Overview
According to SPER Market Research, ‘Global Chemotherapy-Induced Neutropenia Treatment Market Growth, Size, Trends Analysis – By Treatment Type, By Drug Type, By Route of Administration, By Distribution Channel – Regional Outlook, Competitive Strategies and Segment Forecast to 2034’ state that the Global Chemotherapy-Induced Neutropenia Treatment Market is predicted to reach 895.55 million by 2034 with a CAGR of 3.96%.
Chemotherapy-induced neutropenia (CIN) frequently occurs as a side effect of chemotherapy. Neutropenia is characterized by a reduction in the number of neutrophils, a variety of white blood cells essential for combating infections. The administration of chemotherapy drugs inhibits the bone marrow’s capacity to generate neutrophils, resulting in a weakened immune response and heightened vulnerability to infections. As a consequence, CIN may lead to delays or reductions in chemotherapy doses, thus affecting the overall effectiveness of the treatment.
Scope of the report:
Report Metric Details
Market size available for years 2021-2034
Base year considered 2024
Forecast period 2025-2034
Segments covered
By Treatment Type, By Drug Type, By Route of Administration, By Distribution Channel
Regions covered
North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa
Companies Covered
Amgen Inc, BeyondSpring Inc, Biocon Biologics Inc, Cellerant Therapeutics, Coherus BioSciences, Inc, Evive Biotech, Kyowa Kirin Co., Ltd, Novartis AG, Pfizer Inc, Sanofi.
Global Chemotherapy-Induced Neutropenia Treatment Market Segmentation:
By Treatment Type: Based on the Treatment Type, Global Chemotherapy-Induced Neutropenia Treatment Market is segmented as; Granulocyte colony-stimulating factor therapy, Antibiotics, Granulocyte transfusion, Antifungals, Other treatment type.
By Drug Type: Based on the Drug Type, Global Chemotherapy-Induced Neutropenia Treatment Market is segmented as; Branded, Biosimilars.
By Route of administration: Based on the Route of administration, Global Chemotherapy-Induced Neutropenia Treatment Market is segmented as; Parenteral, Oral.
By Distribution Channel: Based on the Distribution Channel, Global Chemotherapy-Induced Neutropenia Treatment Market is segmented as; Hospital pharmacies, Retail pharmacies, Online pharmacies.
By Region: This research also includes data for North America, Latin America, Asia-Pacific, Europe, Middle East & Africa.
According to SPER Market Research, ‘Global Chemotherapy-Induced Neutropenia Treatment Market Growth, Size, Trends Analysis – By Treatment Type, By Drug Type, By Route of Administration, By Distribution Channel – Regional Outlook, Competitive Strategies and Segment Forecast to 2034’ state that the Global Chemotherapy-Induced Neutropenia Treatment Market is predicted to reach 895.55 million by 2034 with a CAGR of 3.96%.
Chemotherapy-induced neutropenia (CIN) frequently occurs as a side effect of chemotherapy. Neutropenia is characterized by a reduction in the number of neutrophils, a variety of white blood cells essential for combating infections. The administration of chemotherapy drugs inhibits the bone marrow’s capacity to generate neutrophils, resulting in a weakened immune response and heightened vulnerability to infections. As a consequence, CIN may lead to delays or reductions in chemotherapy doses, thus affecting the overall effectiveness of the treatment.
Scope of the report:
Report Metric Details
Market size available for years 2021-2034
Base year considered 2024
Forecast period 2025-2034
Segments covered
By Treatment Type, By Drug Type, By Route of Administration, By Distribution Channel
Regions covered
North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa
Companies Covered
Amgen Inc, BeyondSpring Inc, Biocon Biologics Inc, Cellerant Therapeutics, Coherus BioSciences, Inc, Evive Biotech, Kyowa Kirin Co., Ltd, Novartis AG, Pfizer Inc, Sanofi.
Global Chemotherapy-Induced Neutropenia Treatment Market Segmentation:
By Treatment Type: Based on the Treatment Type, Global Chemotherapy-Induced Neutropenia Treatment Market is segmented as; Granulocyte colony-stimulating factor therapy, Antibiotics, Granulocyte transfusion, Antifungals, Other treatment type.
By Drug Type: Based on the Drug Type, Global Chemotherapy-Induced Neutropenia Treatment Market is segmented as; Branded, Biosimilars.
By Route of administration: Based on the Route of administration, Global Chemotherapy-Induced Neutropenia Treatment Market is segmented as; Parenteral, Oral.
By Distribution Channel: Based on the Distribution Channel, Global Chemotherapy-Induced Neutropenia Treatment Market is segmented as; Hospital pharmacies, Retail pharmacies, Online pharmacies.
By Region: This research also includes data for North America, Latin America, Asia-Pacific, Europe, Middle East & Africa.
Table of Contents
243 Pages
- 1. Introduction
- 1.1. Scope of the report
- 1.2. Market segment analysis
- 2. Research Methodology
- 2.1. Research data source
- 2.1.1. Secondary Data
- 2.1.2. Primary Data
- 2.1.3. SPERs internal database
- 2.1.4. Premium insight from KOLs
- 2.2. Market size estimation
- 2.2.1. Top-down and Bottom-up approach
- 2.3. Data triangulation
- 3. Executive Summary
- 4. Market Dynamics
- 4.1. Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1. Drivers
- 4.1.2. Restraints
- 4.1.3. Opportunities
- 4.1.4. Challenges
- 5. Market variable and outlook
- 5.1. SWOT Analysis
- 5.1.1. Strengths
- 5.1.2. Weaknesses
- 5.1.3. Opportunities
- 5.1.4. Threats
- 5.2. PESTEL Analysis
- 5.2.1. Political Landscape
- 5.2.2. Economic Landscape
- 5.2.3. Social Landscape
- 5.2.4. Technological Landscape
- 5.2.5. Environmental Landscape
- 5.2.6. Legal Landscape
- 5.3. PORTERs Five Forces
- 5.3.1. Bargaining power of suppliers
- 5.3.2. Bargaining power of buyers
- 5.3.3. Threat of Substitute
- 5.3.4. Threat of new entrant
- 5.3.5. Competitive rivalry
- 5.4. Heat Map Analysis
- 6. Competitive Landscape
- 6.1. Global Chemotherapy-Induced Neutropenia Treatment Market Manufacturing Base Distribution, Sales Area, Product Type
- 6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Chemotherapy-Induced Neutropenia Treatment Market
- 7. Global Chemotherapy-Induced Neutropenia Treatment Market, By Treatment Type (USD Million) 2021-2034
- 7.1. Granulocyte colony-stimulating factor therapy
- 7.2. Antibiotics
- 7.3. Granulocyte transfusion
- 7.4. Antifungals
- 7.5. Other treatment type
- 8. Global Chemotherapy-Induced Neutropenia Treatment Market, By Drug Type (USD Million) 2021-2034
- 8.1. Branded
- 8.2. Biosimilars
- 9. Global Chemotherapy-Induced Neutropenia Treatment Market, By Route of Administration (USD Million) 2021-2034
- 9.1. Parenteral
- 9.2. Oral
- 10. Global Chemotherapy-Induced Neutropenia Treatment Market, By Distribution Channel (USD Million) 2021-2034
- 10.1. Hospital pharmacies
- 10.2. Retail pharmacies
- 10.3. Online pharmacies
- 11. Global Chemotherapy-Induced Neutropenia Treatment Market, (USD Million) 2021-2034
- 13.1. Global Chemotherapy-Induced Neutropenia Treatment Market Size and Market Share
- 12. Global Chemotherapy-Induced Neutropenia Treatment Market, By Region, (USD Million) 2021-2034
- 12.1. Asia-Pacific
- 12.1.1. Australia
- 12.1.2. China
- 12.1.3. India
- 12.1.4. Japan
- 12.1.5. South Korea
- 12.1.6. Rest of Asia-Pacific
- 12.2. Europe
- 12.2.1. France
- 12.2.2. Germany
- 12.2.3. Italy
- 12.2.4. Spain
- 12.2.5. United Kingdom
- 12.2.6. Rest of Europe
- 12.3. Middle East and Africa
- 12.3.1. Kingdom of Saudi Arabia
- 12.3.2. United Arab Emirates
- 12.3.3. Qatar
- 12.3.4. South Africa
- 12.3.5. Egypt
- 12.3.6. Morocco
- 12.3.7. Nigeria
- 12.3.8. Rest of Middle-East and Africa
- 12.4. North America
- 12.4.1. Canada
- 12.4.2. Mexico
- 12.4.3. United States
- 12.5. Latin America
- 12.5.1. Argentina
- 12.5.2. Brazil
- 12.5.3. Rest of Latin America
- 13. Company Profile
- 13.1. Amgen Inc
- 13.1.1. Company details
- 13.1.2. Financial outlook
- 13.1.3. Product summary
- 13.1.4. Recent developments
- 13.2. BeyondSpring Inc
- 13.2.1. Company details
- 13.2.2. Financial outlook
- 13.2.3. Product summary
- 13.2.4. Recent developments
- 13.3. Biocon Biologics Inc
- 13.3.1. Company details
- 13.3.2. Financial outlook
- 13.3.3. Product summary
- 13.3.4. Recent developments
- 13.4. Cellerant Therapeutics
- 13.4.1. Company details
- 13.4.2. Financial outlook
- 13.4.3. Product summary
- 13.4.4. Recent developments
- 13.5. Coherus BioSciences, Inc
- 13.5.1. Company details
- 13.5.2. Financial outlook
- 13.5.3. Product summary
- 13.5.4. Recent developments
- 13.6. Evive Biotech
- 13.6.1. Company details
- 13.6.2. Financial outlook
- 13.6.3. Product summary
- 13.6.4. Recent developments
- 13.7. Kyowa Kirin Co., Ltd
- 13.7.1. Company details
- 13.7.2. Financial outlook
- 13.7.3. Product summary
- 13.7.4. Recent developments
- 13.8. Novartis AG
- 13.8.1. Company details
- 13.8.2. Financial outlook
- 13.8.3. Product summary
- 13.8.4. Recent developments
- 13.9. Pfizer Inc
- 13.9.1. Company details
- 13.9.2. Financial outlook
- 13.9.3. Product summary
- 13.9.4. Recent developments
- 13.10. Sanofi
- 15.10.1. Company details
- 15.10.2. Financial outlook
- 15.10.3 Product summary
- 15.10.4. Recent developments
- 13.11. Others
- 14. Conclusion
- 15. List of Abbreviations
- 16. Reference Links
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.